STAT proteins: novel molecular targets for cancer drug discovery

By J. Turkson, R. Jove. Oncogene, 2000

678 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c06186bb0f3a9d37f3e2a39e8319d5c207d958c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Jacqueline F. Bromberg
2. R. Jove
3. D. Altieri
4. Hua Yu
5. L. Ellis
6. Gautam Sethi
7. Eric B. Haura
8. C. Heinlein

In Oncology

1. R. Jove
2. Hua Yu
3. Jacqueline F. Bromberg
4. D. Pardoll
5. D. Altieri
6. R. Buettner
7. L. Ellis
8. Eric B. Haura

In Pathology and Forensic Medicine

1. R. Jove
2. Jacqueline F. Bromberg
3. D. Altieri
4. D. Pardoll
5. Hua Yu

Citations in the corpus

• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002, background): “Because Stat3 represents a point of convergence for many oncogenic as well as angiogenic events, Stat3 is a promising molecular target for powerful intervention in cancer therapy (Turkson and Jove, 2000).”
• Survivin, versatile modulation of cell division and apoptosis in cancer (2003, background): “…E-mail: dario.altieri@umassmed.edu Oncogene (2003) 22, 8581–8589 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc cytoprotection (Shen et al., 2001), which may have direct consequences for oncogenic transformation (Turkson and Jove, 2000) (Figure 2).”
• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “The current knowledge of STAT3 signaling pathway allows the study of numerous strategies to suppress STAT3 activation such as inhibiting the receptor ligand complexes, blocking the kinases that phosphorylate the cytoplasmic tail of the receptor, inducing the activity of the phosphatases that dephosp”
• Stat proteins and oncogenesis. (2002, background): “The JAK2 inhibitor AG490, first used against leukemia cells in which the kinase is constitutively active (33), has more recently been found to induce growth arrest or apoptosis in many tumor-derived cell lines, suggesting that this kinase is important in a variety of cancers (34).”
• Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. (2002, background): “It has been deduced from many different studies investigating STAT signaling (using established cell lines, primary cell cultures, and animal models as well as clinical tumor samples with matched adjacent normal tissues), that constitutively activated Stat3 and Stat5 actively participate in tumor de”
• Androgen receptor in prostate cancer. (2004, background): “Inhibition of STAT3 in multiple myeloma-derived cells and in a head and neck squamous cell carcinoma xenograft enhanced apoptosis, suggesting that STAT3 may be an important mediator of cell survival in some cancer types (314, 315) and raising the possibility that the AR-STAT3 interaction could promo”